Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?
Sponsor: Genentech, Inc.
This NA trial investigates Breast Cancer Metastases and HER2 Positive Breast and is currently completed. Genentech, Inc. leads this study, which shows 12 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Sep 2021 — Jul 2024 [monthly]
Completed NA
-
Jan 2021 — Sep 2021 [monthly]
Completed NA
-
Aug 2020 — Jan 2021 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Oct 2019 — Aug 2020 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Nov 2018 — Oct 2019 [monthly]
Recruiting NA
-
Oct 2018 — Nov 2018 [monthly]
Recruiting NA
-
Jun 2018 — Oct 2018 [monthly]
Recruiting NA
-
Oct 2017 — Jun 2018 [monthly]
Recruiting NA
Status: Active Not Recruiting → Recruiting
-
Feb 2017 — Oct 2017 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genentech, Inc.
- Memorial Sloan Kettering Cancer Center
- United States Department of Defense
For direct contact, visit the study record on ClinicalTrials.gov .